محبوبترین نویسندگان :
نویسندگان مقالات پربازدید :
گوارش و بیماری های گوارشی
جزئیات رویداد
اینستاگرام تی پی بین
همایش ، رویداد ، ژورنال
حوزه های تحت پوشش رویداد

  • long-term efficacy of treatment with lamivudine in hbeag-negative patients with decompensated cirrhosis due to chronic hepatitis b

    نویسندگان :
    کلمات کلیدی :
    جزئیات بیشتر مقاله
    • تاریخ ارائه: 1392/07/24
    • تاریخ انتشار در تی پی بین: 1392/07/24
    • تعداد بازدید: 825
    • تعداد پرسش و پاسخ ها: 0
    • شماره تماس دبیرخانه رویداد: -
     the prognosis of patients with decompensated cirrhosis due to hepatitis b is very poor. it has been shown that lamivudine can improve liver function and delay the need for liver transplantation in hbeag-positive patients with decompensated cirrhosis. however, information regarding long-term use of lamivudine in hbeag-negative patients with cirrhosis is limited. the primary objective of this study was to evaluate the long-term efficacy of lamivudine in hbeag-negative/hbeab-positive patients with decompensated cirrhosis. 54 consecutive hbeag-negative/hbeab-positive patients with decompensated cirrhosis were enrolled into this study. all patients were treated with 100 mg lamivudine per day. significant clinical improvement was defined as a decrease of at least 2 points in child-pugh-turcotte (cpt) score. repeated-measure one-way analysis of variance was used to evaluate the effect of time interval of lamivudine treatment on different variables. kaplan-meier survival analysis and mantel-cox test were used to further analyze the data. the mean±sd age of patients was 50.6±13.2 years. there were 40 male and 14 female patients. the median follow-up was 29 (range: 6-64) months. cpt score, meld score and blood chemistries changed significantly after 6 months of therapy. the favorable changes were continued up to 2 years. in spite of worsening after 3 years, within subject effects measured by repeated-measure anova, were significant for patients who have received lamivudine for 4 years or more. long-term lamivudine therapy improves liver function in hbeag-negative/hbeab-positive patients with decompensated cirrhosis.

سوال خود را در مورد این مقاله مطرح نمایید :

با انتخاب دکمه ثبت پرسش، موافقت خود را با قوانین انتشار محتوا در وبسایت تی پی بین اعلام می کنم
مقالات جدیدترین رویدادها
مقالات جدیدترین ژورنال ها